Myriad Genetics has asked the Supreme Court to dismiss the Association for Molecular Pathology’s case against the company, arguing a lack of jurisdiction. If it does not throw out the case, the high court should uphold the Federal Circuit’s ruling that isolated DNA can be patented, Myriad says.
Washington Drug Letter